Overview
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. It is not strictly a peptide — it is a dinucleotide of nicotinamide and adenine — but it is included in peptide research libraries because it underpins many of the cellular pathways targeted by ageing-research peptides.
NAD+ functions as a redox cofactor in glycolysis, the citric-acid cycle and oxidative phosphorylation, and as a substrate for enzymes that hydrolyse the nicotinamide-ribose bond: the sirtuins (SIRT1-7), PARPs, and CD38. Through these enzymes NAD+ controls gene expression, DNA repair, and immune signalling.
Cellular NAD+ pools decline measurably with age across multiple tissues. Whether this decline is causal in ageing pathology or downstream of it is the central open question driving the field; the answer determines whether direct supplementation translates into durable benefit.
Mechanism of Action
As a coenzyme, NAD+ accepts and donates electrons in dehydrogenase reactions, cycling between NAD+ and its reduced form NADH. The ratio of these two species is one of the cell's principal indicators of metabolic state.
As a substrate, NAD+ is consumed by sirtuins to deacetylate target proteins (including histones, FOXO3, p53), by PARPs to ribosylate DNA-damage repair complexes, and by CD38 to generate cyclic ADP-ribose. Each consumption event splits NAD+ into nicotinamide and ADP-ribose; the nicotinamide is recycled through the salvage pathway.
Direct intravenous administration raises plasma NAD+ acutely; oral precursors (NR, NMN) raise it more gradually through the salvage pathway. Tissue-level translation is variable and is the subject of active clinical-trial work.
Research Summary
- NAD+ and sirtuin signalling decline with age; this relationship is reviewed across multiple tissue systems. [1]
- Sirtuin activity is NAD+-dependent; reviews describe how NAD+ availability gates sirtuin-mediated longevity signalling. [2]
- Chronic oral nicotinamide riboside supplementation was well tolerated and significantly raised blood NAD+ in a controlled human trial. [3]
- Intravenous NAD+ precursor administration raised NAD+ levels in preclinical pharmacology studies; human dose-response data remain limited. [4]
What we don't know yet
- Which delivery route best translates into durable tissue-level NAD+ increases is unresolved.
- Long-term safety of chronic high-dose precursor supplementation is still under study.
- Whether NAD+ restoration reverses any specific age-related pathology in humans has not been demonstrated.
Protocol Considerations
Research framing only. The Protides Research Library does not provide dosing guidance for human use. The figures below summarise published research-protocol ranges and storage conditions; they are not clinical recommendations.
Stack Interactions
Storage & Handling
- Lyophilised
- −20 °C, desiccated, dark.
- Reconstituted
- 2–8 °C; NAD+ in solution oxidises measurably over days.
- Shelf life
- Lyophilised ≥ 24 months at −20 °C. Reconstituted use within ~7 days.
FAQ
Is NAD+ a peptide?
No. It is a dinucleotide. It is included here because of its centrality to longevity-peptide research.
What is the difference between NAD+, NR and NMN?
NAD+ is the active coenzyme. NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are precursors that the cell converts to NAD+ through the salvage pathway.
Does intravenous NAD+ work better than oral precursors?
It raises plasma NAD+ faster and higher; whether that translates into better tissue-level outcomes is an active research question.
Why does NAD+ decline with age?
Multiple mechanisms: increased CD38 activity, decreased biosynthesis, and greater PARP consumption from accumulated DNA damage.
Is NAD+ supplementation safe long-term?
Short-term safety is well established; long-term high-dose safety remains under study.
Why does the solution turn yellow?
Oxidation. A pale yellow tint indicates significant degradation; clear solutions are preferred.
References
- [1]NAD+ and sirtuins in aging and diseaseTrends Cell Biol., 2014
- [2]It takes two to tango: NAD+ and sirtuins in aging/longevity controlNPJ Aging Mech. Dis., 2016
- [3]
- [4]
